Titan Pharmaceuticals (NASDAQ:TTNP) Issues Earnings Results

Titan Pharmaceuticals (NASDAQ:TTNP) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, Zacks reports.

Titan Pharmaceuticals Stock Performance

Shares of Titan Pharmaceuticals stock traded down $0.08 during trading on Thursday, reaching $3.58. The stock had a trading volume of 968 shares, compared to its average volume of 135,436. The stock has a fifty day moving average price of $3.60 and a two-hundred day moving average price of $4.09. Titan Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $14.80.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Titan Pharmaceuticals in a report on Monday. They issued a “sell” rating on the stock.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.